Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SAB Biotherapeutics, Inc. (SABS : NSDQ)
 
 • Company Description   
SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D.

Number of Employees: 86

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.90 Daily Weekly Monthly
20 Day Moving Average: 1,097,378 shares
Shares Outstanding: 76.46 (millions)
Market Capitalization: $298.21 (millions)
Beta: 0.55
52 Week High: $5.15
52 Week Low: $1.60
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 2.63% -2.38%
12 Week -5.57% -12.70%
Year To Date 4.28% -6.34%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
777 W 41st St Suite 401
-
Miami Beach,FL 33140
USA		 ph: 605-679-6980
fax: -		 kgardner@lifesciadvisors.com http://www.sab.bio
 
 • General Corporate Information   
Officers
Samuel J. Reich - Chief Executive Officer and Director
David Zaccardelli - Chairman of the Board
Eddie J. Sullivan - President and Director
Christoph Bausch - Chief Operating Officer
Lucy To - Chief Financial Officer

Peer Information
SAB Biotherapeutics, Inc. (CORR.)
SAB Biotherapeutics, Inc. (RSPI)
SAB Biotherapeutics, Inc. (CGXP)
SAB Biotherapeutics, Inc. (BGEN)
SAB Biotherapeutics, Inc. (GTBP)
SAB Biotherapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 78397T202
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/06/26
Share - Related Items
Shares Outstanding: 76.46
Most Recent Split Date: 1.00 (0.10:1)
Beta: 0.55
Market Capitalization: $298.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.29 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.18 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.31
Price/Cash Flow: 11.41
Price / Sales: -
EPS Growth
vs. Year Ago Period: 37.50%
vs. Previous Quarter: 23.91%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/26 - -0.29
12/31/25 - 15.17
09/30/25 - 33.39
ROA
03/31/26 - -0.25
12/31/25 - 12.51
09/30/25 - 25.33
Current Ratio
03/31/26 - 11.45
12/31/25 - 9.46
09/30/25 - 10.49
Quick Ratio
03/31/26 - 11.45
12/31/25 - 9.46
09/30/25 - 10.50
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -
09/30/25 - 16,294.78
Book Value
03/31/26 - 2.97
12/31/25 - 3.18
09/30/25 - 3.48
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.01
12/31/25 - 0.02
09/30/25 - 0.02
Debt-to-Capital
03/31/26 - 1.34
12/31/25 - 2.02
09/30/25 - 1.88
 

Powered by Zacks Investment Research ©